OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Diabetes & Endocrinology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Direct-to-consumer services: improving access to care for people with diabetes and obesity	811
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	708
South Africa to produce insulin for Africa in 2024	667
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	625
Anand Hardikar: a scientific nomad searching for the truth	523
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	507
What's preventing us from curbing the obesity crisis?	502
Reassessing driving safety in diabetes	463
Better testing and labelling of drugs for people with obesity	455
A framework for improving diabetes care in humanitarian emergencies	434
World Health Assembly ratifies first global diabetes targets	428
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	373
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	322
Artificial intelligence and diabetes: time for action and caution	255
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	249
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	237
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	206
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	196
Implications of technology guidelines for low-income and middle-income countries	184
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	177
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	174
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	167
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	166
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	160
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	158

What does renal failure teach us about our National Health System?	156
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	155
Putting wellbeing at the core of diabetes care	144
A roadmap for integrating mental health and diabetes services	142
Cardiovascular mortality trends among people with and without diabetes	141
Challenging diabetes stigma starts and ends with all of us	139
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	135
Glycaemic index as part of the diabetes prevention strategy	134
Healthy weight for the next generation's health in China	131
Lebanon: insulin out of reach after subsidies lifted	130
Jennifer Manne-Goehler: at the crossroads of pandemics	126
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	124
The role of nurses in diabetes care: challenges and opportunities	124
The changing character of diabetes complications	111
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	109
The uncomfortable truth about kidney disease in type 1 diabetes	102
The promise and hope of GLP-1 receptor agonists	101
Rising diabetes diagnosis in long COVID	101
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	101
The urgent need for a diabetes data rights charter	99
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial	93
Childhood obesity: a growing pandemic	92
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England	89
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	88
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	88
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	87
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	84
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X	84
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	84
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	84
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	83
CONCEPTT to care: the science of implementation in diabetes care	83
Understanding the mechanism of prediabetes remission in young people	82
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	81
Women in diabetes research: stepping towards equity	79
Homing in on the causes of male infertility	79
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	78
Diabetes: knowing your risk matters	77
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	76
Gender equality: timely and timeless	76
Improving HbA1c levels with advanced hybrid closed-loop therapy	75
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	73
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	72
Is it time to re-assess the development of thyroid function reference ranges?	70
Blood pressure control according to type 2 diabetes status	70
The long and winding road to precision diabetology	69
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	68
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	66
Male hypogonadism: pathogenesis, diagnosis, and management	65
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	64

Hypothalamic obesity: from basic mechanisms to clinical perspectives	64
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	63
Glucagon, from past to present: a century of intensive research and controversies	63
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	63
Improving support for university students with type 1 diabetes	62
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	62
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes	61
Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28	59
Central diabetes insipidus from a patient's perspective	59
On the occasion of International Women's Day	58
Chronicling insulin from discovery to crisis	58
Teplizumab approval for type 1 diabetes in the USA	57
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	57
Embracing community sport to promote global health	56
Diagnosing diabetes in African populations: a twist in the tale	56
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	55
Has the WHO Model Essential Medicines List lost its way?	55
Management of menopause: a view towards prevention	54
Screening type 1 diabetes and celiac disease by law	54
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	54
Vitamin D and fractures	54
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	53
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	52
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	51
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	51
Automated insulin delivery postpartum: insights from the AiDAPT study extension	50
Young adult-onset type 2 diabetes heralds a poor prognosis	50
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	49
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia	48
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	48
How do clinicians integrate oral octreotide into their treatment plan for acromegaly?	47
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	47
Methodological considerations in D-health cancer mortality results – Authors' reply	47
Technology for type 1 diabetes: what impact will it have?	46
Correction to Lancet Diabetes Endocrinol 2025; 13: 909–10	46
Insulin regimens during type 1 diabetes pregnancy	46
More options for young children with type 1 diabetes	46
Blood glucose targets in the critically ill: is one size fits all still appropriate?	45
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	45
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	44
How clinically relevant is statin-induced diabetes?	43
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	43
Diabetes and cancer in the age of multimorbidity	43
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	42
Disparities in fragility fracture and osteoporosis care in Africa	42
Life stage transitions for people with type 1 diabetes	41
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	41
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	41
MarÍa José Redondo: rethinking type 1 diabetes	40
From reproduction to metabolism: FSH as a key modulator in menopause	40
Enhancing global access to diabetes medicines: policy lessons from the HIV response	40
ORION-3: delivering lipid lowering treatment for longer	40
An inclusive approach to people with disabilities in diabetes care and education	40
Is the impact of add on heart failure therapy influenced by background therapy?	39
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	39
Creating diabetes guidelines for the individual not just the illness	39
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	39
RETRACTED: Targeting of vitamin D supplementation to individuals with deficiency	38
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	38
Addressing health and demographic challenges in Japan's ageing society	38
Viswanathan Mohan: a dynasty of diabetology	38
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	37
Risks and burdens of incident diabetes in long COVID: a cohort study	36
Impact of higher BMI on cardiometabolic risk: does height matter?	36
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	36
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	36
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	36
Redefining obesity: advancing care for better lives	36
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	35
The growing global burden of thyroid cancer overdiagnosis	35
Disease modifying therapies in diabetes and endocrinology	34
Iodine deficiency in Europe: vigilance and action required	33
Mendelian randomisation and vitamin D: the importance of model assumptions	33
Data processing in the DMagic cluster randomised controlled trial	32
Diabetes and the WHO Model List of Essential Medicines	32
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	32
Improving type 1 diabetes care globally: the importance of medical education	31
What's in a decade?	31
From prominent corneal nerves to multiple endocrine neoplasia type 2B	31
Setmelanotide: new promise for the treatment of hypothalamic obesity?	31

The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula	30
Incretins and the cardiovascular system: bridging digestion with metabolism	30
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis	29
Sleep: a neglected public health issue	29
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	28
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	28
Osteoporosis in men	27
The potential role for artificial intelligence in fracture risk prediction	27
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	27
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	27
Maternal thyroid hypofunction and gestational diabetes risk	26
The double burden of poor diets	26
Sex differences in familial hypercholesterolaemia	26
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	26
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial	25
Heterogeneity in type 2 diabetes trajectories: informing public health approaches	23
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	23
Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care	23
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	23
Revisiting osteoporosis guidelines	23
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	23
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	23
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	23
Bariatric surgery in children with obesity and type 2 diabetes	22
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	22
From research to policy: still a long way to go	22
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	22
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	21
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	21
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	21
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	21
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	20
The power of resilience	20
A global plastics treaty to protect endocrine health	20
Peripheral CB1 receptor blockade for treatment of obesity	20
PFAS: here today—here tomorrow	20
Endocrine health in survivors of adult-onset cancer	19
Addressing the educational needs of older adults with type 1 diabetes	19
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	19
Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden	19
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	18
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	18
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	18
Does tirzepatide treatment improve skeletal muscle composition?	18
Sexual dimorphism in COVID-19: potential clinical and public health implications	18
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	18
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	18
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	18
The voices of lived experience in diabetes and endocrinology	17
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	17
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	17
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	17
COVID-19 targets human adrenal glands	17
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	17
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	16
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	16
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	15
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	15
Predicting and preventing heart failure in type 2 diabetes	15
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium	15
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	15